ALLOHealthcare · BiotechnologyThe 12 Wall Street analysts covering Allogene Therapeutics, Inc. hold a median 12-month price target of $9 — +405.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 78 of 100 as at 12 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Allogene Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (83): Analysts have, on balance, been raising their forecasts.
Volatility (40): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ALLO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +405.6% from it.
Of the 20 most recent actions, 6 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Aug 2026 | Citizens | Reiterates | Market Outperform | $6.00 |
| 16 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | $12 → $11 |
| 16 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 16 Apr 2026 | JP Morgan | Upgrade | Neutral | — |
| 16 Apr 2026 | JP Morgan | Upgrade | Neutral | — |
| 15 Apr 2026 | Jefferies | Maintains | Buy | $6.00 → $10 |
| 15 Apr 2026 | Jefferies | Maintains | Buy | — |
| 14 Apr 2026 | Argus Research | Maintains | Market Perform | — |
| 14 Apr 2026 | Argus Research | Maintains | Market Perform | $1.60 → $3.85 |
| 14 Apr 2026 | Baird | Maintains | Outperform | $7.00 → $9.00 |
| 14 Apr 2026 | Baird | Maintains | Outperform | — |
| 14 Apr 2026 | Bernstein | Maintains | Market Perform | — |
| 14 Apr 2026 | Bernstein | Maintains | Market Perform | $1.60 → $3.85 |
| 14 Apr 2026 | Citizens | Maintains | Market Outperform | $5.00 → $8.00 |
| 14 Apr 2026 | Citizens | Maintains | Market Outperform | — |
| 14 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | $8.00 → $12 |
| 14 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Mar 2026 | Canaccord Genuity | Maintains | Buy | — |
| 13 Mar 2026 | Piper Sandler | Maintains | Overweight | — |
| 9 Jan 2026 | Citizens | Upgrade | Market Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ALLO appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, Allogene Therapeutics, Inc. returned +52.1% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 85% of US stocks
Cheaper than 4% of US stocks
Cheaper than 58% of US stocks
Cheaper than 72% of US stocks
Higher than 5% of US stocks
Higher than 30% of US stocks
Higher than 24% of US stocks
Higher than 18% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Allogene Therapeutics, Inc. has a market value of $615.0M and an enterprise value of $361.4M.
Revenue in the twelve months to 30 June 2026: $4.6M.
Net income over the same four quarters: −$165.5M, a −3566.7% net margin.
Diluted earnings per share, trailing twelve months: $−0.67.
Free cash flow in the twelve months to 30 June 2026: −$102.6M.
Trailing P/E: −2.0×; forward P/E: −2.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Allogene Therapeutics, Inc. employs 150 people — $31K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Allogene Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Allogene Therapeutics reported earnings 30 days ago, and its stock has declined 11.1% since that report. The article raises the question of whether the stock can rebound.
Why it matters — Investors following ALLO would care about how the stock has performed since the latest earnings report and whether it may recover.
Allogene Therapeutics presented at Citigroup's Biopharma Back to School Summit 2026, with a transcript of the presentation published by Seeking Alpha. The item reports on the company's participation in the investor conference.
Why it matters — An ALLO watcher would care because the presentation gives investors an opportunity to hear directly from the company's leadership about its business and strategy.
Seeking Alpha welcomed 25 new analysts in August, showcasing their stock picks and investment strategies with ratings ranging from Strong Sell to Strong Buy. Allogene Therapeutics was highlighted among the key bullish investment theses presented by these analysts.
Why it matters — A ALLO watcher would care because Allogene Therapeutics was featured as one of the bullish stock picks among Seeking Alpha's newly added analysts.
Allogene Therapeutics announced that Geoffrey Parker, its Executive Vice President and Chief Financial Officer, will retire effective November 6, 2026. The announcement was made on September 2, 2026.
Why it matters — A leadership change in the CFO role could affect Allogene's financial stewardship and company leadership during its clinical-stage development.
Allogene Therapeutics announced that it will participate in an investor conference in September. The announcement was made on Aug. 31, 2026, from the company's South San Francisco headquarters.
Why it matters — The participation signals upcoming investor-facing engagement that may provide updates on the company's allogeneic CAR T product development.
The 12 Wall Street analysts covering Allogene Therapeutics, Inc. have a median 12-month price target of $9, with estimates ranging from $4 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 12 analysts covering Allogene Therapeutics, Inc., 11 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Allogene Therapeutics, Inc. 78 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, Allogene Therapeutics, Inc. ranks 78 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (83 of 100).
No one can know that. What the data says: the median 12-month target from 12 analysts implies +405.6% from the last close, and Ticker Nerd's factor model ranks Allogene Therapeutics, Inc. 78 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Allogene Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALLO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $14 over the next 12 months.
Allogene Therapeutics, Inc. returned +52.1% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Allogene Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic, or donor-derived, CAR T cell therapies for cancer and autoimmune disease.
The most recent item we track (Zacks Investment Research, 11 Sept 2026): "Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound?". Allogene Therapeutics reported earnings 30 days ago, and its stock has declined 11.1% since that report. The article raises the question of whether the stock can rebound.
Allogene Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic, or donor-derived, CAR T cell therapies for cancer and autoimmune disease. The company’s current work centers on investigational off-the-shelf cell therapy candidates designed to be manufactured from healthy donor cells and delivered more readily to patients than individualized treatments. Its pipeline includes programs targeting blood cancers, solid tumors, and autoimmune disorders, with emphasis on areas such as large B-cell lymphoma, renal cell carcinoma, and other oncology indications. Allogene Therapeutics also develops supporting technologies and manufacturing capabilities that are intended to improve the consistency, scalability, and accessibility of its cell therapy platform. Headquartered in South San Francisco, California, Allogene Therapeutics plays a specialized role in the immuno-oncology market as a developer of next-generation cell therapies for complex diseases.
CEO Dr. Zachary J. Roberts M.D., Ph.D. · 150 employees · United States · https://allogene.com
